SEC 13F Intelligence

Managers / Q1 2022 · view latest →

TRV GP IV, LLC

CIK 0001688325 · 201 BROOKLINE AVE, SUITE 1401, BOSTON, MA, 02215 · 617-585-2000

Reported Value
$273M
Q1 2022
Positions
5
Filings on Record
30
2019–present window
Filed
May 10, 2022
original filing

Summary

Trv GP IV, LLC reported $273M in U.S.-listed holdings across 5 positions for Q1 2022.

The portfolio is heavily concentrated: TNGX alone accounts for 53.8% of reported value.

The book was largely unchanged from Q4 2021.

Portfolio Metrics

Turnover
+4.7%
vs prior filed quarter
Largest Position
+53.8%
Tango Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $46MQ4 ’18Q1 ’19: $132MQ2 ’19: $118MQ3 ’19: $98MQ4 ’19: $160MQ4 ’19Q1 ’20: $109MQ2 ’20: $217MQ3 ’20: $290MQ4 ’20: $312MQ4 ’20Q1 ’21: $271MQ2 ’21: $210MQ3 ’21: $441MQ4 ’21: $348MQ4 ’21Q1 ’22: $273MQ2 ’22: $152MQ3 ’22: $171MQ4 ’22: $235MQ4 ’22Q1 ’23: $140MQ2 ’23: $111MQ3 ’23: $265MQ4 ’23: $246MQ4 ’23Q1 ’24: $206MQ2 ’24: $202MQ3 ’24: $162MQ4 ’24: $80MQ4 ’24Q1 ’25: $93MQ2 ’25: $163MQ3 ’25: $274MQ4 ’25: $255MQ4 ’25Q1 ’26: $267Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 92.8%Other: 7.2%
  • Common Stock · 92.8% · $253M
  • Other · 7.2% · $20M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TNGXTANGO THERAPEUTICS, INC.HELD+019.36M−$65M$147M
FULCFULCRUM THERAPEUTICS, INC.HELD+02.34M+$14M$55M
PLRXPLIANT THERAPEUTICS, INC.HELD+02.13M−$14M$15M
MAGENTA THERAPEUTICS, INC.HELD+06.76M−$10M$20M
RVMDREVOLUTION MEDICINES, INC.HELD+01.42M+$483,000$36M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

5 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1TNGXTANGO THERAPEUTICS, INC.history →COM53.77%$147M19.36M
2FULCFULCRUM THERAPEUTICS, INC.history →COM20.30%$55M2.34M
3RVMDREVOLUTION MEDICINES, INC.history →COM13.27%$36M1.42M
4MAGENTA THERAPEUTICS, INC.COM7.18%$20M6.76M
5PLRXPLIANT THERAPEUTICS, INC.history →COM5.48%$15M2.13M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$267M2May 7, 202613F-HRchanges · EDGAR ↗
Q4 2025$255M2Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$274M2Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$163M3Aug 8, 202513F-HRchanges · EDGAR ↗
Q1 2025$93M3May 9, 202513F-HRchanges · EDGAR ↗
Q4 2024$80M2Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$162M3Nov 6, 202413F-HRchanges · EDGAR ↗
Q2 2024$202M3Aug 9, 202413F-HRchanges · EDGAR ↗
Q1 2024$206M3May 13, 202413F-HRchanges · EDGAR ↗
Q4 2023$246M3Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$265M3Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$111M3Aug 10, 202313F-HRchanges · EDGAR ↗
Q1 2023$140M3May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$235M5Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$171M5Nov 3, 202213F-HRchanges · EDGAR ↗
Q2 2022$152M5Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$273M5May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$348M5Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$441M5Nov 5, 202113F-HRchanges · EDGAR ↗
Q2 2021$210M4Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$271M4May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$312M5Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$290M5Nov 6, 202013F-HRchanges · EDGAR ↗
Q2 2020$217M4Aug 7, 202013F-HRchanges · EDGAR ↗
Q1 2020$109M3May 11, 202013F-HRchanges · EDGAR ↗
Q4 2019$160M2Feb 5, 202013F-HRchanges · EDGAR ↗
Q3 2019$98M2Nov 4, 201913F-HRchanges · EDGAR ↗
Q2 2019$118M1Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$132M1May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$46M1Jan 28, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.